Modulating the redox tumor microenvironment will therefore, not only inhibit the oncogenic c-Met pathway in cancer cells, but also target the activated phenotype of CAFs, thus suppressing their tumor-stroma interactions. The gene discussed is MET; the disease is neoplasm.